As part of this partnership, Yposkesi will produce lentiviral vector batches to meet Orchard’s needs for clinical trials in primary immune deficiencies including X-linked chronic granulomatous disease.
London (United Kingdom) and Corbeil-Essonnes (France), December 18th 2017- Orchard Therapeutics, a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, announces today a manufacturing agreement with Yposkesi, a leading manufacturing organization for gene and cell therapy products created by AFM-Téléthon and the SPI fund managed by Bpifrance.
Yposkesi provides its expertise and production capacity to Orchard Therapeutics’ projects. As part of this partnership, Yposkesi will produce lentiviral vector batches to meet Orchard’s needs for clinical trials in primary immune deficiencies including X-linked chronic granulomatous (X-CGD) disease.
Mark Rothera, Chief Executive Officer of Orchard Therapeutics comments: “We are excited to work with Yposkesi, an industrial leader in the manufacturing of advanced therapy products. This partnership will help to accelerate the development of Orchard’s transformative gene therapy medicines in some severe hereditary diseases. Yposkesi and Orchard are working to reach a common goal to improve the length and quality of patients’ lives.”
“We are proud to count Orchard Therapeutics among Yposkesi’s customers, and to contribute to innovative therapies development for pathologies for which a therapeutic solution does not exist yet. This agreement is a further proof of Yposkesi’s expertise in gene therapy drug production and demonstrates how actors of tomorrow’s treatment trust in us”, added Alain Lamproye, CEO of Yposkesi.
A PROPOS D’ORCHARD THERAPEUTICS
Orchard Therapeutics is a privately-held clinical-stage biotechnology company based in London, UK and in California, US. Orchard is dedicated to transforming the lives of patients with rare disorders through innovative gene therapies. Orchard works in partnership with some of the world’s leading centers in gene therapy, including University College London, Great Ormond Street Hospital for Children NHS Foundation Trust, the University of Manchester and Manchester University NHS Foundation Trust, the University of California Los Angeles and Boston Children’s Hospital. In 2016 the company was named a Fierce 15 Company by Fierce Biotech. Also, Orchard and UCLA were awarded a $19 million grant from the California Institute of Regenerative Medicine (CIRM) in 2016 to advance the development of autologous ex-vivo lentiviral gene therapy in ADA-SCID. For more information, visit www.orchard-tx.com
A PROPOS D’YPOSKESI
Yposkesi is a European industrial leader for Gene and Cell Therapy with the mission of developing, manufacturing and making available Gene and Cell therapy treatments to patients affected with rare diseases. It was launched in November 2016 in Evry (France) by the patient organization AFM-Téléthon with the support of the SPI fund from the French Public Investment Bank (BPI France), with a total investment of €121M. It is made up of 150 experts in bioproduction and has a first production building covering 5'000 m2. The broad expertise of Yposkesi covers the production of viral vectors for gene therapy (Lentivirus & AAV), transduction of hematopoietic stem cells and production of human pluripotent stem cells, with also significant efforts in developing innovative process for large-scale cost-effective manufacturing process of these highly complex ATMPs. The plans are to extend the production capacity with two additional buildings for a total of 13'000 m2 by 2021.
For more information, please visit our website at: www.yposkesi.com
CONTACTS
| Relations Presse - ALIZE RP |
| Caroline Carmagnol et Aurore Gangloff |
| Mail : yposkesi@alizerp.com |
| Tél. : 01 44 54 36 65 |
| Orchard Therapeutics Limited: Sylvie Blanchier Mail: sylvie.blanchier@orchard-tx.com Tel: +44 (0) 2035 988 960 |
